Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 5/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16681069 | 1.00 | SCN4A (0.50) | SCN4ADPP4F2HTR2ATAAR1 | |
| SCHEMBL1455742 | 1.00 | SCN4A (0.50) | SCN4ADPP4F2HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL25180795 | 0.97 | SCN4A (0.48) | SCN4ADPP4F2HTR2ATAAR1 | |
| Iodide SCHEMBL28728556 | 0.97 | SCN4A (0.48) | SCN4ADPP4F2HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL25180796 | 0.97 | SCN4A (0.48) | SCN4ADPP4F2HTR2ATAAR1 | |
| SCHEMBL6642727 | 0.80 | SCN4A (0.52) | SCN4ADPP4F2HTR2ATAAR1 | |
| SCHEMBL6859189 | 0.78 | DPP4 (0.55) | SCN4ADPP4F2HTR2ATAAR1 | |
| SCHEMBL2781359 | 0.78 | DPP4 (0.55) | SCN4ADPP4F2HTR2ATAAR1 | |
| SCHEMBL16367913 | 0.78 | DPP4 (0.55) | SCN4ADPP4F2HTR2ATAAR1 | |
| SCHEMBL2521653 | 0.78 | DPP4 (0.55) | SCN4ADPP4F2HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101030-A1 | CHIRAL METAL OXIDE-BASED WATER ELECTROLYSIS ELECTRODE, METHOD FOR MANUFACTURING SAME, AND WATER ELECTROLYSIS DEVICE COMPRISING SAME | 한양대학교 산학협력단 | 2026-05-15 | — | — | WO | disclosed |
| CN-117715481-A | Efficient stable two-dimensional perovskite solar cell based on self-addition interval cation directional regulation and control | 安徽大学 | 2024-03-15 | — | — | CN | disclosed |
| CN-112020357-B | Salt of indazolyl-containing tricyclic derivative and crystal form thereof | 上海翰森生物医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-115380030-A | N-heteroarylalkyl-2- (heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists | 武田药品工业株式会社 | 2022-11-22 | — | — | CN | disclosed |
| CN-110546150-B | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-12-21 | — | — | CN | disclosed |
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112020357-A | Salts of indazolyl-containing tricyclic derivatives and crystal forms thereof | 上海翰森生物医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20090170131-A1 | Agents for Imaging Apoptosis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2009-07-02 | — | — | US | disclosed |
| CN-101384655-A | Fluorinated rylenetetracarboxylic acid derivatives and use thereof | BASF SE (DE) | 2009-03-11 | — | — | CN | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| CN-100395234-C | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| WO-2007134127-A2 | AGENTS FOR IMAGING APOPTOSIS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-11-22 | — | — | WO | disclosed |
| CN-101012193-A | Novel CB 1 receptour inverse agonists | HOFFMANN LA ROCHE (CH) | 2007-08-08 | — | — | CN | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1829694-A | quinoline derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| CN-1735593-A | Novel CB1 receptor inverse agonists | HOFFMANN LA ROCHE (CH) | 2006-02-15 | — | — | CN | disclosed |
| CN-1592624-A | Substituted-triazolopyrimidines as anticancer agents | WYETH CORP (US) | 2005-03-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | SCN4A 3834/4885DPP4 1119/4885F2 4302/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | SCN4A 2385/4885DPP4 1190/4885F2 3435/4885 |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | SCN4A 230/4885DPP4 561/4885F2 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.